SCHEMBL1668412

SCHEMBL1668412

Nc1cc(C(F)(F)F)cnc1S

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.42
KDM4E B2RXH2 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
POLB P06746 2/20 0.42
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
NOS3 P29474 1/20 0.39
NOS2 P35228 1/20 0.39
CFTR P13569 1/20 0.39
PLAU P00749 1/20 0.39
PTPN5 P54829 2/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
PKM P14618 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
AGBL2 Q5U5Z8 1/20 0.35
GAA P10253 2/20 0.35
FEN1 P39748 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30989671 1.00 ALDH1A1 (0.42) ALDH1A1KDM4ESMN1; SMN2POLBCYP1A2
SCHEMBL1716472 0.78 ALDH1A1 (0.44) ALDH1A1KDM4ESMN1; SMN2POLBCYP1A2
SCHEMBL30762204 0.78 ALDH1A1 (0.44) ALDH1A1KDM4ESMN1; SMN2POLBCYP1A2
Methane SCHEMBL28200241 0.77 ALDH1A1 (0.43) ALDH1A1KDM4ESMN1; SMN2POLBCYP1A2
SCHEMBL11181913 0.77 ALDH1A1 (0.43) ALDH1A1KDM4ESMN1; SMN2POLBCYP1A2
Hydrochloric Acid SCHEMBL3038475 0.77 ALDH1A1 (0.43) ALDH1A1KDM4ESMN1; SMN2POLBCYP1A2
SCHEMBL10148411 0.77 ALDH1A1 (0.38) ALDH1A1KDM4ESMN1; SMN2POLBPLAU
SCHEMBL756227 0.75 ALDH1A1 (0.50) ALDH1A1KDM4ESMN1; SMN2POLBCYP1A2
SCHEMBL1027863 0.75 ALDH1A1 (0.44) ALDH1A1KDM4ESMN1; SMN2POLBCYP1A2
SCHEMBL573513 0.75 CYP1A2 (0.43) ALDH1A1KDM4ESMN1; SMN2POLBCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260103464-A1 CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2026-04-16 US disclosed
US-12435083-B2 Cyclopropyl-(hetero)aryl-substituted ethylsulphonyl-pyridine derivatives BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2025-10-07 US disclosed
CN-118355004-A Cyclopropyl- (heteroaryl) -substituted ethylsulfonyl-pyridine derivatives 勃林格殷格翰动物保健有限公司 2024-07-16 CN disclosed
CN-110891566-B Synthesis method and synthesis intermediate 塔克西斯医药股份有限公司 2023-12-19 CN disclosed
US-20230257397-A1 SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES TAXIS PHARMACEUTICALS, INC. (US) 2023-08-17 US disclosed
US-20230257397-A1 SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES TAXIS PHARMACEUTICALS, INC. (US) 2023-08-17 US disclosed
US-20230257397-A1 SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES TAXIS PHARMACEUTICALS, INC. (US) 2023-08-17 US disclosed
US-20230234951-A1 CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2023-07-27 US disclosed
US-20230234951-A1 CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2023-07-27 US disclosed
US-20230234951-A1 CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2023-07-27 US disclosed
EP-2655337-A1 FUSED HETEROCYCLIC COMPOUND AND USE FOR PEST CONTROL THEREOF Sumitomo Chemical Company Limited (JP) 2013-10-30 EP disclosed
CN-103261170-A Fused heterocyclic compounds and their use for pest control SUMITOMO CHEMICAL CO 2013-08-21 CN disclosed
WO-2013018928-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF FOR PEST CONTROL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-02-07 WO disclosed
CN-102686585-A Heterocyclic compound and its use for control of an arthropod pest SUMITOMO CHEMICAL CO 2012-09-19 CN disclosed
EP-2486035-A1 HETEROCYCLIC COMPOUND AND ITS USE FOR CONTROL OF AN ARTHROPOD PEST Sumitomo Chemical Co., Ltd (JP) 2012-08-15 EP disclosed
US-20120196891-A1 HETEROCYCLIC COMPOUND AND ITS USE FOR CONTROL OF AN ARTHROPOD PEST SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-08-02 US disclosed
US-20120196891-A1 HETEROCYCLIC COMPOUND AND ITS USE FOR CONTROL OF AN ARTHROPOD PEST SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-08-02 US disclosed
WO-2012086848-A1 FUSED HETEROCYCLIC COMPOUND AND USE FOR PEST CONTROL THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-06-28 WO disclosed
WO-2011043404-A1 HETEROCYCLIC COMPOUND AND ITS USE FOR CONTROL OF AN ARTHROPOD PEST SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-04-14 WO disclosed
WO-2011043404-A1 HETEROCYCLIC COMPOUND AND ITS USE FOR CONTROL OF AN ARTHROPOD PEST SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234951-A1 CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES CYCS, CYP2E1, AHR ALDH1A1 637/4885KDM4E 930/4885SMN1; SMN2 4334/4885
US-20230257397-A1 SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES TXN, TBXAS1, TXK ALDH1A1 4470/4885KDM4E 3798/4885SMN1; SMN2 3456/4885
US-20120196891-A1 HETEROCYCLIC COMPOUND AND ITS USE FOR CONTROL OF AN ARTHROPOD PEST HAAO, DDT, ACHE ALDH1A1 533/4885KDM4E 1844/4885SMN1; SMN2 1085/4885
US-12435083-B2 Cyclopropyl-(hetero)aryl-substituted ethylsulphonyl-pyridine derivatives CYCS, CYP2E1, CYP1A1 ALDH1A1 512/4885KDM4E 1000/4885SMN1; SMN2 4257/4885
US-20260103464-A1 CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES CBR3, CYCS, CBR1 ALDH1A1 2267/4885KDM4E 3064/4885SMN1; SMN2 3977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.